Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
|
SE |
|
G
|
Globex Mining Enterprise Inc
F:G1MN
|
CA |
Intrinsic Value
The intrinsic value of 
Swedish Orphan Biovitrum AB (publ) (BIOVF) under the Base Case is 46.01 USD per share.
Compared with the current market price of 42.8 USD, the stock appears
Undervalued by 7% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
Revenue & Expenses Breakdown
Swedish Orphan Biovitrum AB (publ)
Earnings Waterfall
Swedish Orphan Biovitrum AB (publ)
The intrinsic value for Swedish Orphan Biovitrum AB (publ) (BIOVF) under the Base Case is 46.01 USD.
Compared with the current market price of 42.8 USD, the stock appears Undervalued by 7% .